TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28557869

Group type: EXPERIMENTAL
Intervention: Suprathel (S)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mepilex Ag (M)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 62
Study: 27637517

Group type: EXPERIMENTAL
Intervention: Tobacco Cessation on Prescription (TCP)
Number of subjects: 928

Group type: COMPARATOR
Intervention: Current practice for tobacco cessation
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 928
Study: 24799299

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 14
Study: 22270205

Group type: EXPERIMENTAL
Intervention: 17 mouse units (m.U) of Botox
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 17 mouse units (m.U) of Prosigne
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 17 mouse units (m.U) of Xeomin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 51 Speywood units (s.U) of Dysport
Number of subjects: 12

Group type: COMPARATOR
Intervention: All BTXA preparations combined
Number of subjects: 12
Study: 20046175

Group type: EXPERIMENTAL
Intervention: Single dose 400 mg itraconazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: 7 day 200 mg daily itraconazole
Number of subjects: 60
Study: 18520221

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS) technique without supplementary ligation (NT group)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional hand-tied ligation technique (CT group)
Number of subjects: 65
Study: 15860465

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT) for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (COMT) for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: No Training (NT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Strength Training (COMT)
Number of subjects: 31
Study: 11396535

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days followed by 3 weeks of RBC 400 mg b.d. alone
Number of subjects: 102
Study: 9935258

Group type: EXPERIMENTAL
Intervention: 300 mg alatrofloxacin daily followed by 200 mg oral trovafloxacin daily
Number of subjects: 308

Group type: COMPARATOR
Intervention: 1 g imipenem/cilastatin intravenously thrice daily followed by 500 mg oral amoxicillin/clavulanic acid thrice daily
Number of subjects: 308
Study: 8058076

Group type: EXPERIMENTAL
Intervention: 400 micrograms of budesonide per day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 1200 micrograms of budesonide per day (crossover group)
Number of subjects: 74
Study: 11039067

Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel with 98% available Sn2+ ion, used twice daily for nine months
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.4% SnF2 gel with less than 2% available Sn2+ ion, used once a day for six months, then twice a day for three months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Toothbrushing alone (control group)
Number of subjects: 81
Study: 8130476

Group type: EXPERIMENTAL
Intervention: ComputerLink (electronic network designed to support home care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ComputerLink
Number of subjects: 0
Study: 347857

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined oestrogen/androgen compound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31629880

Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance Training (IRT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham Control (PLA)
Number of subjects: 28
Study: 31295393

Group type: EXPERIMENTAL
Intervention: In-office technique (40%HP, Opalescence Boost) in three sessions (40 minutes each)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: At-home technique (10%HP, Opalescence GO) for 15 days (1 hour per day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined technique (initial session with 40%HP, followed by 10%HP for 15 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: All techniques (at-home, in-office, combined)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: In-office technique
Number of subjects: 75
Study: 28091532

Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg b.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26987135

Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (59.1 ± 12.1 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ivabradine (12.1 ± 4.6 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (Metoprolol and Ivabradine)
Number of subjects: 100
Study: 23959319

Group type: EXPERIMENTAL
Intervention: Micafungin with higher maximum concentrations of drug in serum (Cmax) and large, infrequent doses
Number of subjects: 2

Group type: COMPARATOR
Intervention: Micafungin with lower doses
Number of subjects: 2
Study: 21120743

Group type: EXPERIMENTAL
Intervention: Hyperoxic gas (99.5 ± 0.2 % F(I)O(2))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no external supplementation)
Number of subjects: 7
Study: 19961366

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy without subcostal and lateral trocars (LCWSL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 60
Study: 17276446

Group type: EXPERIMENTAL
Intervention: SVC segmental ostial isolation (SOI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pulmonary vein (PV) segmental ostial isolation (SOI)
Number of subjects: 95
Study: 15157139

Group type: EXPERIMENTAL
Intervention: Intervention involving picking referents of novel nouns from pairs of familiar objects (Experiments 1 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention involving teaching subordinate names for familiar objects (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhyme-sensitization procedure (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment impact
Number of subjects: 0
Study: 11204052

Group type: EXPERIMENTAL
Intervention: Epidural opioid (fentanyl)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epidural local anesthetic (bupivacaine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no opioids)
Number of subjects: 10
Study: 9510492

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 66

Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 66
Study: 8032803

Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) imaging
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scintigraphic (SC) volume estimations
Number of subjects: 20
Study: 3281060

Group type: EXPERIMENTAL
Intervention: Alizapride 50 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alizapride 200 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 90
Study: 29222619

Group type: EXPERIMENTAL
Intervention: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour (10 individual sessions with a dietician and a physiotherapist).
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (CG; CPAP and advice about weight loss).
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour.
Number of subjects: 86
Study: 28314618

Group type: EXPERIMENTAL
Intervention: Drop punt kicking
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (10min of sitting)
Number of subjects: 36
Study: 25522824

Group type: EXPERIMENTAL
Intervention: Frequency-modulated steady-state visual evoked potentials (FM-SSVEPs) with carrier frequencies of 20Hz and above
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sinusoidally evoked SSVEPs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rectangularly evoked SSVEPs
Number of subjects: 0
Study: 23381968

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study: 21421501

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (CPB)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (non-CPB)
Number of subjects: 48
Study: 19453846

Group type: EXPERIMENTAL
Intervention: MYC gene amplification
Number of subjects: 236
Study: 17142063

Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 3900 mg
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 1950 mg
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 15135695

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 496

Group type: COMPARATOR
Intervention: Silicon carbon-coated stent implantation
Number of subjects: 496
Study: 11294665

Group type: EXPERIMENTAL
Intervention: vCP205 plus gp120
Number of subjects: 435

Group type: COMPARATOR
Intervention: vCP205 alone
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: vCP205 with or without gp120
Number of subjects: 435
Study: 9710686

Group type: EXPERIMENTAL
Intervention: 0.1/0.06 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 0.2/0.1 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 0.4/0.15 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 143
Study: 7800117

Group type: EXPERIMENTAL
Intervention: Glyceryl trioleate and trierucate oils (Lorenzo's Oil)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated ALD patients)
Number of subjects: 14
Study: 2647535

Group type: EXPERIMENTAL
Intervention: 2% ketanserin ointment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (polyethylene glycol base)
Number of subjects: 23
Study: 31504116

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (HND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 0
Study: 29179781

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt (339 g daily for 9 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (soya pudding 324 g daily for 9 weeks)
Number of subjects: 60
Study: 26069170

Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 22887465

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Esophagectomy
Number of subjects: 81
Study: 21727299

Group type: EXPERIMENTAL
Intervention: Self-regulation-depletion group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 19368788

Group type: EXPERIMENTAL
Intervention: 0.1mL intradermal influenza vaccine
Number of subjects: 197

Group type: COMPARATOR
Intervention: 0.5mL intramuscular influenza vaccine
Number of subjects: 197
Study: 16752244

Group type: EXPERIMENTAL
Intervention: Effective intravaginal electrical stimulation (IES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham intravaginal electrical stimulation (IES)
Number of subjects: 40
Study: 15027082

Group type: EXPERIMENTAL
Intervention: Multivariate Plackett-Dale model for survival outcomes
Number of subjects: 0
Study: 11504318

Group type: EXPERIMENTAL
Intervention: Active treatment (nortriptyline)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9133547

Group type: EXPERIMENTAL
Intervention: Trimethaphan (0.3-0.6 mg/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Regular human insulin (0.28 pmol x m(-2) x min(-1)) with variable rate glucose infusion
Number of subjects: 7
Study: 8404789

Group type: EXPERIMENTAL
Intervention: Standard breakfast
Number of subjects: 279

Group type: COMPARATOR
Intervention: Fasting (no breakfast)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Both conditions (breakfast and fasting)
Number of subjects: 279
Study: 2419384

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with cat- and dog-dander extracts
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 30640216

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 500
Study: 29420073

Group type: EXPERIMENTAL
Intervention: 380 mg intramuscular injections of long‐acting naltrexone on study day 1 and at the start of study week 5
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 25602170

Group type: EXPERIMENTAL
Intervention: Adolescent Behavioral Activation Program (A-BAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncontrolled evidenced-based practice for depression
Number of subjects: 60
Study: 25245464

Group type: EXPERIMENTAL
Intervention: Dorsal position
Number of subjects: 321

Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 321
Study: 21674691

Group type: EXPERIMENTAL
Intervention: Sequential finger tapping task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomly ordered finger-tapping task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selectivity index
Number of subjects: 0
Study: 19413822

Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at 2 l x min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at 4 l x min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at 6 l x min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at all flow rates
Number of subjects: 13
Study: 17554647

Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Late colonoscopy
Number of subjects: 86
Study: 15865530

Group type: EXPERIMENTAL
Intervention: Video game practicing (group B)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 11
Study: 12100641

Group type: EXPERIMENTAL
Intervention: Manual pressure applied before intramuscular injection for 10 seconds
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional injection without manual pressure
Number of subjects: 74
Study: 9707377

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 199
Study: 7883836

Group type: EXPERIMENTAL
Intervention: Alprazolam (2 mg, orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1298937

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 56

Group type: COMPARATOR
Intervention: Upper GI series
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ultrasound negative and X-ray positive
Number of subjects: 56
Study: 6380254

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingual)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30783704

Group type: EXPERIMENTAL
Intervention: Telephone follow-up (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-person clinic visits (n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 29680872

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.7%
Number of subjects: 2

Group type: COMPARATOR
Intervention: Olopatadine 0.2%
Number of subjects: 2
Study: 26891655

Group type: EXPERIMENTAL
Intervention: Tailored movement control exercise intervention (MC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: General exercise intervention (GE)
Number of subjects: 106
Study: 24293165

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg daily) for 3 months followed by amiodarone for 15 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo for 15 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (9 untreated patients undergoing ECV)
Number of subjects: 51
Study: 22434466

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated tibial components
Number of subjects: 291

Group type: COMPARATOR
Intervention: Cemented components
Number of subjects: 291
Study: 20074810

Group type: EXPERIMENTAL
Intervention: First depressive episode
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Second depressive episode
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: First recovery period
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Second recovery period
Number of subjects: 267
Study: 18164527

Group type: EXPERIMENTAL
Intervention: Older group (aged adults)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proverb comprehension task
Number of subjects: 0
Study: 16446685

Group type: EXPERIMENTAL
Intervention: Soy protein (40 g protein/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Whey protein (40 g protein/day)
Number of subjects: 18
Study: 14609102

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% ointment applied twice daily for 21 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vehicle (corresponding vehicle ointment)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Calcipotriol 0.005% ointment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clobetasol-17-propionate 0.05% ointment
Number of subjects: 23
Study: 10576237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TAM 10 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TAM 20 mg/day
Number of subjects: 43
Study: 7851682

Group type: EXPERIMENTAL
Intervention: Insulin infusion at rates of 0.25, 1.0, and 10.0 mU.kg‐1.min‐1 in donor subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp during insulin infusion in donor subjects
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Minimal model technique for insulin sensitivity and glucose effectiveness in donor subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects maintained at euglycaemia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects during hyperglycaemic clamp
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects using minimal model technique
Number of subjects: 24
Study: 2671283

Group type: EXPERIMENTAL
Intervention: CMFVP (combination cyclophosphamide 60 mg/m2 orally every day for 1 year; fluorouracil 300 mg/m2 IV weekly for 1 year; methotrexate 15 mg/m2 IV weekly for 1 year; vincristine 0.625 mg/m2 IV for 10 weeks; prednisone 30 mg/m2 orally days 1 to 14, 20 mg/m2 days 15 to 28, 10 mg/m2 days 29 to 42)
Number of subjects: 441

Group type: COMPARATOR
Intervention: L‐PAM (single‐agent melphalan 5 mg/m2 orally every day for 5 days every 6 weeks for 2 years)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: CMFVP
Number of subjects: 441

Group type: COMPARATOR
Intervention: L‐PAM
Number of subjects: 441
Study: 339787

Group type: EXPERIMENTAL
Intervention: fenoterol (0.4 mg t.i.d. or q.i.d.)
Number of subjects: 44

Group type: COMPARATOR
Intervention: isoproterenol (0.15 mg t.i.d. or q.i.d.)
Number of subjects: 44
Study: 31833059

Group type: EXPERIMENTAL
Intervention: 12-hour maintenance dose of magnesium sulfate (MgSO4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 24-hour maintenance dose of magnesium sulfate (MgSO4)
Number of subjects: 80
Study: 30900158

Group type: EXPERIMENTAL
Intervention: Nivestym (PF-06881893) 5 μg/kg subcutaneously as a single injection
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Nivestym (PF-06881893) 5 μg/kg subcutaneously as five consecutive daily injections
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Nivestym (PF-06881893)
Number of subjects: 340

Group type: COMPARATOR
Intervention: US-Neupogen (filgrastim)
Number of subjects: 340
Study: 28670132

Group type: EXPERIMENTAL
Intervention: Totally laparoscopic aortobifemoral bypass surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open aortobifemoral bypass surgery
Number of subjects: 50
Study: 25775741

Group type: EXPERIMENTAL
Intervention: Wide-awake technique with adrenaline-contained lidocaine (no tourniquet applied)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional group with lidocaine (no adrenaline) and a 250-mmHg tourniquet application
Number of subjects: 60
Study: 24170534

Group type: EXPERIMENTAL
Intervention: Research abstracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-text manuscripts access
Number of subjects: 0
Study: 22065870

Group type: EXPERIMENTAL
Intervention: Supervised exercise training programme (ETP) with 36 structured gym-based 1 hour sessions over 24 weeks, tailored to exercise capacity including aerobic, resistance, and balance exercises.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group DMP includes individualized education and follow-up from a multidisciplinary heart failure team; a weekly education programme for 12 weeks; self-management advice; and medical follow-up.
Number of subjects: 350
Study: 18805773

Group type: EXPERIMENTAL
Intervention: Diclofenac-orphenadrine infusion (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tramadol (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac-orphenadrine and tramadol (Group C)
Number of subjects: 60
Study: 16599097

Group type: EXPERIMENTAL
Intervention: Duraphat (fluoride varnish)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SuperSeal (oxalate preparation)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Duraphat
Number of subjects: 48

Group type: COMPARATOR
Intervention: SuperSeal
Number of subjects: 48
Study: 15314424

Group type: EXPERIMENTAL
Intervention: Right anterior oblique position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time after feeding
Number of subjects: 20